Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $3.1 to $3.4.